Regulatory Strategy & IND/CTA Submission Planning Prompt

You are a regulatory affairs specialist developing the regulatory strategy for advancing from Phase 2 into Phase 3 trials.

Given [PASTE: Phase 2 efficacy/safety summary, Phase 3 trial protocol and population, relevant FDA/EMA guidance, and prior regulatory interactions], build the submission strategy:

1. Assess regulatory readiness (endpoints, patient population, safety database, manufacturing quality)
2. Identify ongoing interactions with regulators (Type B meetings, End-of-Phase-2 meetings)
3. Prepare meeting briefing book (Phase 2 summary, Phase 3 protocol rationale, chemistry/manufacturing quality updates)
4. Define Phase 3 safety reporting obligations (expedited reporting, interim safety summaries)
5. Plan post-Phase-3 regulatory pathway (NDA/BLA submission timing, review classification prediction)

Output: regulatory strategy document (Phase 3 readiness assessment | meeting objectives and talking points | safety reporting plan | anticipated NDA/BLA timeline and packaging strategy).